

mb
C17
A1

2. (Amended) The pharmaceutical composition of claim 1, wherein the hsp110 polypeptide is complexed with the immunogenic polypeptide.

3. (Amended) The pharmaceutical composition of claim 2, wherein the hsp110 polypeptide is complexed with the immunogenic polypeptide by non-covalent interaction.

4. The pharmaceutical composition of claim 2, wherein the complex comprises a fusion protein.

5. The pharmaceutical composition of claim 1, wherein the complex is derived from a tumor.

6. The pharmaceutical composition of claim 1, wherein the complex is derived from a cell infected with an infectious agent.

7. The pharmaceutical composition of claim 1, wherein the stress protein complex further comprises a polypeptide selected from the group consisting of members of the hsp70, hsp90, grp78 and grp94 stress protein families.

8. The pharmaceutical composition of claim 1, wherein the stress protein complex comprises hsp110 complexed with hsp70 and hsp25.

A2 mb
C1 A1

9. (Amended) A pharmaceutical composition comprising a first polynucleotide encoding an hsp110 polypeptide and a second polynucleotide encoding an immunogenic polypeptide.

10. The pharmaceutical composition of claim 9, wherein the first polynucleotide is linked to the second polynucleotide.

11-15. (Canceled)

A3 mb
C17

16. (Amended) The pharmaceutical composition of claim 1, wherein the immunogenic polypeptide comprises a cancer antigen.

17. The pharmaceutical composition of claim 16, wherein the immunogenic polypeptide comprises a hcr-2/neu peptide.

18. The pharmaceutical composition of claim 17, wherein the her-2/neu peptide is derived from the intracellular domain of her-2/neu.

19. (Amended) The pharmaceutical composition of claim 17, wherein the her-2/neu peptide is derived from the extracellular domain of her-2/neu.

20. (Amended) The pharmaceutical composition of claim 17, wherein the her-2/neu peptide is derived from the transmembrane region of her-2/neu.

21. (Amended) The pharmaceutical composition of claim 16, wherein the cancer is colon cancer.

22. (Amended) The pharmaceutical composition of claim 1, wherein the complex has been heated so as to enhance binding of the hsp110 polypeptide to the immunogenic polypeptide.

23. The pharmaceutical composition of claim 1, further comprising an adjuvant.

24-32. (Canceled)

33. (Amended) A method for inhibiting tumor growth in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 16 to elicit an anti-tumor immune response in the subject, and thereby inhibiting tumor growth in the subject.

34. (Amended) A method for inhibiting the development of a cancer in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 16 to elicit an anti-tumor immune response in the subject, and thereby inhibiting the development of a cancer in the subject.

35-45. (Canceled)

46. (New) The method of claim 32, wherein the hsp110 polypeptide of the pharmaceutical composition is complexed with the immunogenic polypeptide.

47. (New) The method of claim 32, wherein the hsp110 polypeptide of the pharmaceutical composition is complexed with the immunogenic polypeptide by non-covalent interaction.

48. (New) The method of claim 32, wherein the complex of the pharmaceutical composition comprises a fusion protein.
49. (New) The method of claim 32, wherein the complex of the pharmaceutical composition is derived from a tumor.
50. (New) The method of claim 32, wherein the hsp110 of the pharmaceutical composition is complexed with hsp70 and hsp25.
51. (New) The method of claim 32, wherein the immunogenic polypeptide of the pharmaceutical composition comprises a her-2/neu peptide.
52. (New) The method of claim 51, wherein the her-2/neu peptide is derived from the intracellular domain of her-2/neu.
53. (New) The method of claim 51, wherein the her-2/neu peptide is derived from the extracellular domain of her-2/neu.
54. (New) The method of claim 51, wherein the her-2/neu peptide is derived from the transmembrane region of her-2/neu.
55. (New) The method of claim 32, wherein the cancer is colon cancer.
56. (New) The method of claim 32, wherein the complex of the pharmaceutical composition has been heated so as to enhance binding of the hsp110 polypeptide to the immunogenic polypeptide.
57. (New) The method of claim 32, wherein the pharmaceutical composition further comprises an adjuvant.
58. (New) The method of claim 33, wherein the hsp110 polypeptide of the pharmaceutical composition is complexed with the immunogenic polypeptide.
59. (New) The method of claim 33, wherein the hsp110 polypeptide of the pharmaceutical composition is complexed with the immunogenic polypeptide by non-covalent interaction.